Evidence map›Paper›PMID 28542693›Full record

ArticleJAMA ophthalmology2017

Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.

Etienne M Schönbach, Yulia Wolfson, Rupert W Strauss, Mohamed A Ibrahim, Xiangrong Kong, Beatriz Muñoz, David G Birch, Artur V Cideciyan, Gesa-Astrid Hahn, Muneeswar Nittala and 5 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in JAMA ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01977846 (Natural History of Progression of Atrophy Secondary to Stargardt Disease), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01977846 completednot on this map

Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease

TypeobservationalSponsorFoundation Fighting BlindnessRan2013 to 2017Enrolled259ConditionsStargardt Disease
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies.International journal of molecular sciences · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Effects of Photo-Biomodulation in Stargardt Disease.Clinical ophthalmology (Auckland, N.Z.) · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 5 countries.

Etienne M SchönbachWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Yulia WolfsonWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Rupert W StraussWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland2Moorfields Eye Hospital, London, United Kingdom3Department of Ophthalmology, Johannes Kepler University, Linz, Austria4Department of Ophthalmology, Medical University, Graz, Austria5Department of Ophthalmology, University of Basel, Switzerland.
Mohamed A IbrahimWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Xiangrong KongWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Beatriz MuñozWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
David G BirchRetina Foundation of the Southwest, Dallas, Texas.
Artur V CideciyanScheie Eye Institute, University of Pennsylvania, Philadelphia.
Gesa-Astrid HahnCenter for Ophthalmology, Eberhard Karls Universität, Tübingen, Germany.
Muneeswar NittalaDoheny Eye Institute, Los Angeles, California.
Janet S SunnessHoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, Baltimore, Maryland.
SriniVas R SaddaDoheny Eye Institute, Los Angeles, California11University of California, Los Angeles David Geffen School of Medicine.
Sheila K WestWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Hendrik P N SchollWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland5Department of Ophthalmology, University of Basel, Switzerland.
ProgStar Study Group
Johns Hopkins University · USDoheny Eye Institute · USGreater Baltimore Medical Center · USMoorfields Eye Hospital · GBPenn Presbyterian Medical Center · USRetina Foundation of the Southwest · USUniversity of Basel · CHUniversity of California, Los Angeles · USUniversity of Tübingen · DE

Funding

MEASURES OF HUMAN RECEPTOR AND POST RECEPTOR ACTIVITYR01EY009076 · NEI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI BIRCH, DAVID G, HOOD, DONALD C. · 1991 to 2021
$8.3M
6 · The paper itself

Abstract

Importance: New outcome measures for treatment trials for Stargardt disease type 1 (STGD1) and other macular diseases are needed. Microperimetry allows mapping of light sensitivity of the macula and provides topographic information on visual function beyond visual acuity. Objective: To measure and analyze retinal light sensitivity of the macula in STGD1 using fundus-controlled perimetry (microperimetry). Design, Setting, and Participants: This was a multicenter prospective cohort study. A total of 199 patients and 326 eyes with molecularly confirmed (ABCA4) STGD1 underwent testing with the Nidek MP-1 microperimeter as part of the multicenter, prospective Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) study. Sensitivity of 68 retinal loci was tested, and the mean sensitivity (MS) was determined; each point was categorized as "normal," "relative," or "deep" scotoma. Main Outcomes and Measures: Mean sensitivity and the number of points with normal sensitivity, relative, or deep scotomas. Results: Mean (SD) patient age was 34.2 (14.7) years, mean (SD) best-corrected visual acuity of all eyes was 47.8 (16.9) Early Treatment Diabetic Retinopathy Study letter score (approximately 20/100 Snellen equivalent), and mean MS of all eyes of all 68 points was 11.0 (5.0) dB. The median number of normal points per eye was 49 (mean [SD], 41.3 [20.8]; range, 0-68); abnormal sensitivity and deep scotomas were more prevalent in the central macula. Mean sensitivity was lower in the fovea (mean [SD], 2.7 [4.4] dB) than in the inner (mean [SD], 6.8 [5.8] dB) and outer ring (mean [SD], 12.7 [5.3] dB). Overall MS per eye was 0.086 dB lower per year of additional age (95% CI, -0.13 to -0.041; P < .001) and 0.21 dB lower per additional year of duration of STGD1 (95% CI, -0.28 to -0.14; P < .001). Longer duration of STGD1 was associated with worse MS (β = -0.18; P < .001), with a lower number of normal test points (β = -0.71; P < .001), and with a higher number of deep scotoma points (β = -0.70; P < .001). We found 11 eyes with low MS (<6 dB) but very good best-corrected visual acuity of at least 72 Early Treatment Diabetic Retinopathy Study letter score (20/40 Snellen equivalent). Conclusions and Relevance: We provide an extensive analysis of macular sensitivity parameters in STGD1 and demonstrate their association with demographic characteristics and vision. These data suggest microperimetry testing provides a more comprehensive assessment of retinal function and will be an important outcome measure in future clinical trials.

Indexed as

Visual AcuityAdultDisease ProgressionFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansMacula LuteaMacular DegenerationMaleProspective StudiesRetinal Pigment EpitheliumStargardt DiseaseTomography, Optical CoherenceVisual Fields

Identifiers

PMID28542693
PMCPMC6584711
OpenAlexW2618542869

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.